1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Drugs In Development, 2022, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 4, 4 and 7 respectively.
Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Presbyopia - Overview
- Presbyopia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Presbyopia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Presbyopia - Companies Involved in Therapeutics Development
- AbbVie Inc
- Cellix Bio Pvt Ltd
- Eyenovia Inc
- Glaukos Corp
- KSbitugen Co Ltd
- Kubota Vision Inc
- Lenz Therapeutics LLC
- Novartis AG
- Ocuphire Pharma Inc
- Orasis Pharmaceuticals Ltd
- Plex Pharmaceuticals Inc
- Reven Holdings Inc
- Santen Pharmaceutical Co Ltd
- Seinda Pharmaceutical Guangzhou Corp
- Theratocular Biotek Co Ltd
- Visus Therapeutics Inc
- Vyluma Inc
- Zhejiang Raytone Biotechnology Co Ltd
- Presbyopia - Drug Profiles
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- aceclidine - Drug Profile
- Product Description
- Mechanism Of Action
- AGN-241622 - Drug Profile
- Product Description
- Mechanism Of Action
- CAP-1160 - Drug Profile
- Product Description
- Mechanism Of Action
- CLXOPH-561 - Drug Profile
- Product Description
- Mechanism Of Action
- GLK-302 - Drug Profile
- Product Description
- Mechanism Of Action
- Kinase Derivatives - Drug Profile
- Product Description
- Mechanism Of Action
- KSB-10201 - Drug Profile
- Product Description
- Mechanism Of Action
- KT-101 - Drug Profile
- Product Description
- Mechanism Of Action
- NVK-029 - Drug Profile
- Product Description
- Mechanism Of Action
- phentolamine mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- pilocarpine - Drug Profile
- Product Description
- Mechanism Of Action
- RPEC-1004A - Drug Profile
- Product Description
- Mechanism Of Action
- RTP-003A - Drug Profile
- Product Description
- Mechanism Of Action
- RTP-003B - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Presbyopia and Cataract - Drug Profile
- Product Description
- Mechanism Of Action
- Small-Molecule Therapeutics - Drug Profile
- Product Description
- Mechanism Of Action
- SY-301 - Drug Profile
- Product Description
- Mechanism Of Action
- TOO-1005 - Drug Profile
- Product Description
- Mechanism Of Action
- ursodiol - Drug Profile
- Product Description
- Mechanism Of Action
- VP-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- Presbyopia - Dormant Projects
- Presbyopia - Product Development Milestones
- Featured News & Press Releases
- Nov 02, 2022: Ocuphire announces peer-reviewed publication in BMC Ophthalmology for Nyxol and strategic partnership with American Society of Ophthalmic Administrators (ASOA)
- Oct 28, 2022: Ocuphire announces poster presentations on Nyxol at the American Academy of Optometry Annual Meeting
- Oct 20, 2022: Eyenovia announces positive results from VISION-2 phase 3 study of MicroLine as a potential on-demand treatment for presbyopia
- Oct 03, 2022: Ocuphire announces upcoming presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
- Jul 06, 2022: Eyenovia strategic partner Arctic Vision enrolls first patient in phase III clinical trial of ARVN003 (MicroLine) for Presbyopia in China
- Jul 05, 2022: Arctic Vision enrols first subject in Phase III presbyopia trial
- Apr 27, 2022: Visus Therapeutics announces new scientific data to be presented during the 2022 ARVO Annual Meeting
- Apr 26, 2022: Ocuphire announces upcoming clinical presentation on Nyxol at ARVO 2022 Medical Meeting and MODLive! 2022
- Apr 23, 2022: Orasis Pharmaceuticals announces phase 2b trial efficacy and safety results of novel presbyopia eye drop candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Apr 21, 2022: Orasis Pharmaceuticals announces positive phase 3 topline results of Novel Eye Drop Candidate, CSF-1, for the treatment of presbyopia
- Apr 12, 2022: Orasis Pharmaceuticals to present new data on novel presbyopia candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Mar 22, 2022: Visus Therapeutics initiates phase 3 pivotal trials of BRIMOCHOL PF for the treatment of presbyopia
- Mar 15, 2022: Orasis Pharmaceuticals concludes phase 3 clinical trials for presbyopia candidate
- Feb 08, 2022: Ocuphire completes enrollment in MIRA-3 Pivotal phase 3 clinical trial for Nyxol in RM and announces upcoming medical conference presentation
- Jan 11, 2022: Glaukos announces first patient enrolled in phase 2 clinical trial for presbyopia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Presbyopia, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Presbyopia - Pipeline by AbbVie Inc, 2022
- Presbyopia - Pipeline by Cellix Bio Pvt Ltd, 2022
- Presbyopia - Pipeline by Eyenovia Inc, 2022
- Presbyopia - Pipeline by Glaukos Corp, 2022
- Presbyopia - Pipeline by KSbitugen Co Ltd, 2022
- Presbyopia - Pipeline by Kubota Vision Inc, 2022
- Presbyopia - Pipeline by Lenz Therapeutics LLC, 2022
- Presbyopia - Pipeline by Novartis AG, 2022
- Presbyopia - Pipeline by Ocuphire Pharma Inc, 2022
- Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, 2022
- Presbyopia - Pipeline by Plex Pharmaceuticals Inc, 2022
- Presbyopia - Pipeline by Reven Holdings Inc, 2022
- Presbyopia - Pipeline by Santen Pharmaceutical Co Ltd, 2022
- Presbyopia - Pipeline by Seinda Pharmaceutical Guangzhou Corp, 2022
- Presbyopia - Pipeline by Theratocular Biotek Co Ltd, 2022
- Presbyopia - Pipeline by Visus Therapeutics Inc, 2022
- Presbyopia - Pipeline by Vyluma Inc, 2022
- Presbyopia - Pipeline by Zhejiang Raytone Biotechnology Co Ltd, 2022
- Presbyopia - Dormant Projects, 2022
- Number of Products under Development for Presbyopia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Cellix Bio Pvt Ltd
- Eyenovia Inc
- Glaukos Corp
- KSbitugen Co Ltd
- Kubota Vision Inc
- Lenz Therapeutics LLC
- Novartis AG
- Ocuphire Pharma Inc
- Orasis Pharmaceuticals Ltd
- Plex Pharmaceuticals Inc
- Reven Holdings Inc
- Santen Pharmaceutical Co Ltd
- Seinda Pharmaceutical Guangzhou Corp
- Theratocular Biotek Co Ltd
- Visus Therapeutics Inc
- Vyluma Inc
- Zhejiang Raytone Biotechnology Co Ltd
